首页> 外文期刊>Clinical and experimental hypertension: CEH >Nephroprotection in diabetes mellitus.
【24h】

Nephroprotection in diabetes mellitus.

机译:糖尿病的肾保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Present study analyses nephroprotective effect of various therapeutic interventions at different stages of kidney involvement in diabetes mellitus. A MEDLINE search of past 10 years data on various experimental studies, controlled clinical trials, meta-analysis and editorials pertaining to nephroprotection in diabetes mellitus was made. Effect of various therapeutic interventions such as metabolic glycaemic control, restricted protein diet and antihypertensive drugs (especially ACE inhibitors) has been analysed on the progression of different stages of kidney involvement in diabetes mellitus such as normoalbuminuria, microalbuminuria, diabetic nephropathy and end stage renal disease (ESRD). An attempt has been made to analyse differential long-term impact of various therapeutic interventions in relation to type of diabetes mellitus (i.e., IDDM and NIDDM) and associated hypertension. Progression of IDDM patients having microalbuminuria or diabetic nephropathy with or without hypertension has improved during the past decade largely because of adequate glycaemic control and effective antihypertensive treatment with conventional drugs e.g. beta-blockers and calcium antagonists, and more so due to the use of ACE inhibitors e.g. captopril, enalapril etc. Superiority of ACE inhibitor tends to decline from normotensive stage to the degree of rise in systemic blood pressure. However, data in NIDDM patients suffering from diabetic nephropathy is incomplete and inconclusive.
机译:本研究分析了在糖尿病肾脏累及不同阶段的各种治疗干预措施的肾脏保护作用。进行MEDLINE检索了过去10年的数据,这些数据涉及各种实验研究,对照临床试验,荟萃分析以及与糖尿病肾保护相关的社论。已分析了各种治疗干预措施(例如代谢性血糖控制,限制性蛋白饮食和降压药(尤其是ACE抑制剂))对糖尿病正常肾脏参与不同阶段(如正常白蛋白尿,微量白蛋白尿,糖尿病肾病和终末期肾脏疾病)进展的影响(ESRD)。已经尝试分析与糖尿病类型(即,IDDM和NIDDM)和相关的高血压有关的各种治疗性干预的不同的长期影响。在过去的十年中,患有微蛋白尿或糖尿病性肾病并伴或不伴高血压的IDDM患者的病情进展得到了改善,这在很大程度上是由于适当的血糖控制和使用常规药物(例如,降糖药)的有效降压治疗所致。 β-受体阻滞剂和钙拮抗剂,更重要的是由于使用了ACE抑制剂,例如卡托普利,依那普利等。ACE抑制剂的优越性从血压正常阶段降低到全身性血压升高的程度。但是,患有糖尿病性肾病的NIDDM患者的数据不完整且没有定论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号